The National Institutes of Health said on Thursday the item had partnered 11 biopharma companies to help advance a completely new class of drugs of which uses the body’s immune system to fight cancer.
The all 5-year public-private research collaboration, called Partnership for Accelerating Cancer Therapies, includes drugmakers AbbVie, Roche as well as also Bristol-Myers Squibb.
The completely new class of immunotherapies, such as Roche’s Tecentriq as well as also Bristol-Myers’ Opdivo, works by enlisting the body’s defenses to fight the tumors.
Merck, whose Keytruda leads the fast-expanding field of immunotherapies, is usually not involved within the partnership.
Pfizer, Johnson & Johnson, Amgen, Celgene, Gilead Sciences, as well as also GlaxoSmithKline are part of the effort, NIH said.
The 11 partners would certainly contribute up to $1 million each year for all 5 years, while NIH would certainly add about $0 million, based on availability of funds.
The partnership will be managed by the Foundation for the National Institutes of Health.